Avelumab is an anti-PD-L1 ICI that has not been approved by U.S. FDA to be used in NSCLC, as it failed to show a survival benefit, when compared with chemotherapy in platinum-treated advanced NSCLC patients, in a previous clinical trial (JAVELIN Lung 200) [47]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.